First Trust Nasdaq Pharmaceuticals ETF
FTXH
5 hedge funds and large institutions have $68.2K invested in First Trust Nasdaq Pharmaceuticals ETF in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 3 closing their positions.
24.84% less ownership
Funds ownership: 28.09% → 3.25% (-25%)
29% less funds holding
Funds holding: 7 → 5 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
89% less capital invested
Capital invested by funds: $601K → $68.2K (-$533K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$512K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$17K |
| 3 |
FAAS
First Allied Advisory Services
San Diego,
California
|
-$2K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$1.84K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$154 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Bank of America
Charlotte,
North Carolina
| $42K | -$154 | -7 | -0.3% |
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $12K | – | – | – |
|
|
LTFS
3
Ladenburg Thalmann Financial Services
Miami,
Florida
| $8K | -$1.84K | -84 | -18% |
|
|
APA
4
American Portfolios Advisors
Holbrook,
New York
| $5.24K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $1K | +$1.01K | +46 | New |
|
|
6
Jane Street
New York
| – | -$512K | -23,910 | Closed |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$17K | -784 | Closed |
|
|
FAAS
8
First Allied Advisory Services
San Diego,
California
| – | -$2K | -100 | Closed |
|
FTXH Hedge Fund Activity: Q1 2018 in Review
5 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q1 2018, worth a combined $68.2K — down 89% from $601K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of FTXH and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $1.01K. The largest seller was Jane Street, exiting entirely with an estimated $512K sold.
- 5 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q1 2018, down from 7 in Q4 2017.
- Funds reported $68.2K of First Trust Nasdaq Pharmaceuticals ETF stock for Q1 2018, down 89% quarter-over-quarter.
- 1 fund opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q1 2018 and 3 closed out, a net change of -2 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q1 2018 was Tower Research Capital (TRC), an estimated $1.01K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q1 2018 was Jane Street, an estimated $512K sold.
Based on aggregated 13F filings for Q1 2018.